上证报中国证券网讯 1月13日，恒生指数高开1.32%，恒生科技指数涨1.93%。阿里巴巴-W、阿里健 康、小鹏汽车-W等涨超4%，比亚迪股份涨超3%，哔哩哔哩、腾讯控股等涨超2%。 来源：上海证券报·中国证券网 ...

Core Insights - A milestone solution for infant vascular tumor treatment has been launched in China, with the modified new drug, Malate Timolol Gel (brand name: Beimeijing), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1] - The drug is the first and only approved topical gel formulation for treating "proliferative superficial infantile hemangiomas," marking a significant advancement for China in this medical field [1] - Beimeijing has received national-level price certification, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Overview - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The "golden window period" for effective intervention is within the first 1-6 months after birth, as failure to treat during this period can lead to permanent skin issues [2] - Traditional treatment methods have limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - Beimeijing's development was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, with a comprehensive approach from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and pain-free option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data showed that among 121 infants aged 1-6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4% and good safety profile [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the child, ensuring that the standardized treatment approach represented by Beimeijing reaches every family in need [3]

Core Viewpoint - The AI healthcare concept stocks experienced significant gains in the afternoon trading session, indicating a positive market sentiment towards this sector [1][4]. Stock Performance Summary - Ark Health (06086) saw a remarkable increase of 52.74%, rising by 3.62 HKD [1][4]. - Crystal Tech Holdings (02228) rose by 5.17%, reaching a price of 13.62 HKD [1][4]. - Yimaitong (02192) increased by 4.94%, with a current price of 13.80 HKD [1][4]. - Alibaba Health (00241) experienced a gain of 2.52%, trading at 6.52 HKD [1][4]. - iFlytek Medical Technology (02506) saw a modest increase of 1.30%, priced at 109.10 HKD [1][4].

Market Overview - The Hang Seng Index closed at 26,608 points, up 1.4%, while the Hang Seng China Enterprises Index rose 1.9% to 9,220 points[1] - Total turnover in Hong Kong stocks reached HKD 306.2 billion, a 24.9% increase from HKD 245.1 billion last Friday, indicating positive investor sentiment[1] - Key sectors such as consumer discretionary, information technology, and materials rose by 3.5%, 2.2%, and 2.2% respectively, while energy fell by 0.3%[1] Stock Performance - Alibaba Health (241 HK) and Kuaishou (1024 HK) led the gains, rising by 10.2% and 7.4% respectively[1] - Midea Group (300 HK) and Shenzhou International (2313 HK) were the biggest losers, both down by 2.8%[1] Global Economic Factors - Increasing global uncertainties include investigations into Fed Chair Powell and rising tensions regarding Greenland, which may impact US-EU relations[1] - Oil prices fluctuated between USD 58 and 59 due to expectations of ample supply, while gold prices approached a new high of USD 4,600[1] US Market Insights - The Dow Jones Industrial Average closed at 49,590 points, up 0.2%, amid concerns over Trump's potential interventions in the financial sector[2] - The Hang Seng Index futures closed at 26,994 points, indicating a premium of 386 points, suggesting a continuation of the upward trend in Hong Kong stocks[2] Real Estate Dynamics - In mainland China, the transaction volume of new homes in 30 major cities reached 1.16 million square meters, a year-on-year decline of 39.9%[3] - The decline in transactions was more severe than the previous week's drop of 15.1%, with first, second, and third-tier cities experiencing declines of 41.5%, 34.6%, and 46.8% respectively[3] Industry Highlights - The AI sector in Hong Kong saw significant gains, with companies like SenseTime (20 HK) and Fourth Paradigm (6682 HK) rising by 6.9% and 17.5% respectively[4] - The healthcare index rose by 1.1%, with WuXi Biologics (2269 HK) expected to achieve double-digit revenue growth by 2025[5] Renewable Energy Sector - The photovoltaic sector rebounded, with stocks like Xinyi Solar (968 HK) and Flat Glass Group (6865 HK) increasing by 1.9% to 3.8%[6] - The cancellation of VAT export rebates for photovoltaic products is expected to stabilize export prices in the long term[6]

Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1][3] - Beimeijing® is the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas," marking a critical leap for China in this medical field [3] - The drug's launch coincides with the issuance of the first overseas drug price certification by the National Drug Price Registration System, establishing a traceable price benchmark for Chinese innovative drugs in the international market [3] Clinical Need - Infantile hemangiomas are the most common benign tumors in infants, with an estimated global incidence of 5%-12%, and superficial types accounting for nearly 70% [3][4] - The "golden window period" for effective intervention is within the first 1-6 months after birth, during which rapid proliferation occurs [3][4] - Failure to intervene during this period can lead to permanent skin issues, even if the tumor eventually regresses naturally [4] Innovation and Development - The development of Beimeijing® was based on core patents from a team at Shanghai Jiao Tong University School of Medicine and involved a comprehensive process from molecular design to clinical validation [4][5] - The gel formulation allows for localized application, minimizing systemic exposure and enhancing safety for infants, which is particularly important given their delicate skin [5] - Clinical trial data showed a 60.7% clinical cure rate and an overall efficacy rate of 89.4% after 24 weeks of treatment in infants aged 1-6 months, demonstrating the drug's safety and effectiveness [5] Market Strategy - Alibaba Health is positioned as the launch platform for innovative Chinese drugs, utilizing user insights and digital technology to create a comprehensive service ecosystem for families in need [5] - The collaboration aims to deliver standardized treatment solutions and foster a patient-centered service model for ongoing management of infantile hemangiomas [5]

Market Overview - The three major indices in the A-share market opened higher but fell back, with the Shanghai Composite Index down 0.03%, the Shenzhen Component down 0.31%, and the ChiNext Index down 0.83% as of midday trading [1] - The total trading volume in the Shanghai and Shenzhen markets reached 2.47 trillion yuan, an increase of 215.7 billion yuan compared to the previous trading day [1] Sector Performance - The AI application, lithium mining, gold, and CRO concept stocks were active, while the commercial aerospace sector experienced a significant decline [4] - The commercial aerospace sector saw a sharp adjustment, with many stocks dropping over 10%, including Aerospace Zhizhuang and Platinum Technology, while China Satellite Communications hit the daily limit down [4] - The AI application sector continued to perform strongly, with several stocks hitting the daily limit up, including Yidian Tianxia and Zhiding Mai [5][6] Lithium Market - Lithium carbonate futures broke through the 170,000 yuan/ton mark, reaching a new high since October 2023, with a price increase of approximately 12% [9] - The recent price surge is driven by expectations of downstream stocking due to adjustments in battery export tax policies, which are expected to impact corporate profitability [10] - Demand from the new energy commercial vehicle and energy storage sectors has significantly exceeded expectations, shifting market sentiment from "oversupply" to "tight balance" [10] Gold Market - The gold market experienced slight fluctuations, with spot gold down 0.02% to $4,596.12 per ounce, while silver rose by 0.81% [12] - The Chicago Mercantile Exchange announced changes to the margin requirements for gold and silver contracts, moving to a percentage of the contract's nominal value [14]

1月13日，全球婴儿血管瘤治疗领域迎来一项来自中国的里程碑式解决方案。由北京梅尔森医药技术开 发有限公司历时十二年自主研发的改良型新药——马来酸噻吗洛尔凝胶(商品名：贝美净®)，在阿里健 康全网独家首发。即日起，家长只需通过淘宝搜索"贝美净"，经在线专业问诊后，即可开启科学、安心 的规范治疗。 贝美净®的研发始于上海交通大学医学院附属第九人民医院郑家伟教授团队的核心专利，由梅尔森医药 历经十二年系统性攻关，完成从分子设计、剂型优化到Ⅰ-Ⅲ期临床验证的全链条转化。 其最大突破在于采用外用凝胶剂型——通过局部涂抹，药物精准作用于病灶，有效成分主要集中于血管 瘤组织，显著降低了不必要的全身性暴露风险，尤其契合婴幼儿娇嫩的皮肤，安全性更高。相较于需要 该药物于2025年9月30日获国家药监局批准上市，成为全球首个且目前唯一获批用于治疗"增殖期浅表性 婴儿血管瘤"的外用凝胶制剂，这标志着我国在该疾病领域实现了从跟跑到领跑的关键跨越。 值得关注的是，在贝美净®于阿里健康首发之际，其产品价值亦获得国家级药品价格管理体系的权威认 证。1月13日上午，中国药品价格登记系统同步向贝美净®颁发首张海外版药品价格证明，为中国原研 药 ...

Core Insights - The Chinese healthcare industry has undergone a significant transformation from 2020 to 2025, transitioning from a "golden era" of investment to a "bubble-clearing period" characterized by a K-shaped divergence in market performance [1][2][4]. Group 1: K-shaped Downward Trends - The collapse of previously successful business models, particularly in CXO, consumer healthcare, and internet healthcare, has led to substantial market value losses, with some companies experiencing declines of over 90% [4][7]. - The downturn is attributed to macroeconomic factors such as U.S. interest rate hikes and geopolitical tensions, as well as microeconomic issues like supply-demand imbalances and the disappearance of growth dividends [8][10]. - The CXO sector, once seen as a perpetual growth engine, has faced a 46.68% decline for WuXi Biologics and 44.47% for Tigermed, revealing the fragility of its business model reliant on continuous global financing [12][10]. - Consumer healthcare has suffered a "Davis double whammy," with companies like Yonghe Medical and Aier Eye Hospital seeing declines of 86.19% and 52.69%, respectively, as consumer spending shifts away from discretionary healthcare services [14][15]. - Internet healthcare companies, including Zhiyun Health and Dingdang Health, have also faced severe declines, with drops of 92.44% and 90.67%, as the market realizes that their revenue largely comes from online drug sales rather than innovative healthcare solutions [19][21]. Group 2: K-shaped Upward Trends - In contrast, companies with strong global rights and hard-core technology have thrived, with Keren Biotechnology and Kangfang Biopharma seeing increases of 518.33% and 166.72%, respectively, marking a shift towards biopharma and global market engagement [29][31]. - The rise of these companies signifies a new era where capital is attracted to firms that can demonstrate robust clinical data and global market potential, moving away from mere concepts [30][31]. - Even within struggling sectors, some companies like WuXi AppTec and Yuyue Medical have shown resilience, with increases of 113.36% and 28.75%, respectively, by focusing on high-tech, high-barrier services [34][35]. Group 3: Challenges Ahead - Despite the emergence of new leaders, significant challenges remain, including the risks associated with licensing agreements that may compromise long-term profitability [36][37]. - The ADC sector is experiencing a rush similar to the past PD-1 craze, raising concerns about market saturation and price competition, which could undermine future profitability [39][40]. - The ongoing "ice age" in the primary market poses a threat to innovation, as funding for early-stage companies has become increasingly scarce, potentially leading to a decline in new drug approvals in the coming years [42][43].

Market Overview - The A-share market showed a mixed performance with the Shanghai Composite Index down 0.03% at 4163.84, the Shenzhen Component Index down 0.31% at 14321.80, and the ChiNext Index down 0.83% at 3360.23 as of midday [3][4] - The total trading volume in the Shanghai and Shenzhen markets reached 2.44 trillion yuan, an increase of 128.3 billion yuan compared to the previous trading day, with over 2800 stocks declining [5] Sector Performance - The commercial aerospace sector experienced significant declines, while the computing hardware industry chain, particularly in CPO and server segments, also faced downturns [4] - Conversely, sectors such as AI applications, lithium mining, gold, and CRO concepts showed active trading [4] Notable Stocks - The main contract for Shanghai tin futures surged over 7%, reaching 390,450 yuan per ton, marking a new high since March 2022 [6] - Lithium carbonate futures on the Guangzhou Futures Exchange hit the daily limit, trading at 174,060 yuan per ton with an increase of 11.99% [7] - The oil and gas extraction and service sector saw a rebound, with stocks like Tongyuan Petroleum rising over 10% [8] Insurance Sector - The insurance sector showed strength, with China Life Insurance rising over 4%, reaching its highest level since January 2008, and New China Life Insurance increasing over 5% [11] AI and Healthcare Stocks - AI healthcare and pharmaceutical stocks continued to rise, with companies like Huaren Health and Sichuang Medical reaching their daily limit [8] Opening Trends - The Hong Kong market opened positively, with the Hang Seng Index up 1.32% and the Hang Seng Tech Index up 1.93%, driven by gains in tech stocks such as Alibaba and XPeng Motors [22]

Group 1 - The core viewpoint of the news is that AI healthcare concept stocks are experiencing significant gains, driven by a partnership between Nvidia and Eli Lilly to invest $1 billion in a joint research lab to accelerate AI applications in the pharmaceutical industry [1][2] - Ark Health (06086) saw a rise of 30.8%, while other AI healthcare stocks like Medical Pulse (02192) and Crystal Technology Holdings (02228) also reported increases of 5.1% and 4.63% respectively [1] - The joint lab established by Nvidia and Eli Lilly aims to generate large-scale data and build AI models to enhance new drug development, with operations expected to start early this year [1] Group 2 - According to Fengzheng Securities, AI-driven healthcare is forming a new growth engine, with a positive outlook on the revolutionary potential of AI in pharmaceuticals, basic research, diagnosis, and health management [2] - Huafu Securities noted that the AI healthcare industry has entered a critical stage of commercialization, supported by national strategies and market demand, with a closed-loop demand for AI applications sustaining the sustainable development of the AI industry [2]